BP11131 PLGA 65:35, Carboxyl-Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa

PLGA 65:35, Carboxyl-Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Description

PLGA 65:35, Carboxyl-Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa is a copolymer of lactic and glycolic acids with a 65:35 ratio, modified with carboxyl terminal groups. The specified intrinsic viscosity and molecular weight range determine its degradation behaviour and mechanical integrity. This composition facilitates its use in applications where gradual polymer erosion and biocompatibility are critical for performance.

PLGA 65:35, Carboxyl-Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Applications

1.         Healthcare Applications
   - Used as a scaffold component in tissue engineering to achieve controlled cell growth by leveraging predictable biodegradation rates.
   - Applied in bioresorbable implant systems to manage drug release kinetics by exploiting its hydrolytic degradation properties.

2.         Pharmaceutical Applications
   - Employed as a matrix in controlled drug delivery devices to achieve sustained therapeutic release by utilising its defined molecular weight and degradation profile.
   - Serves as a carrier in injectable depot formulations to maintain dosage consistency through gradual polymer erosion.

3.         Research Applications
   - Used as a model polymer in biomaterials research to investigate degradation behaviour and cell-material interactions by leveraging its well-characterised properties.

PLGA 65:35, Carboxyl-Terminated, IV: 0.18–0.25 dl/g, Mw: 15–24 kDa Packing

The product is packaged in airtight, moisture-resistant containers to prevent contamination and degradation. Protective materials such as anti-static and cushioned inserts are used during shipment. Storage in a cool, dry environment is recommended to maintain polymer integrity. Custom packaging options, including inert atmosphere sealing, are available upon request to meet specific research or industrial protocols.

Additional Information

Biodegradable polymers like PLGA are extensively studied for their ability to safely degrade into non-toxic byproducts. Their controlled erosion profiles make them suitable for a variety of biomedical applications, particularly where transient support during tissue regeneration is required. The scientific community values detailed characterisation data, such as intrinsic viscosity and molecular weight, to predict in vivo performance.

In the broader context of biomaterials, understanding polymer degradation kinetics is crucial for designing systems that interact effectively with biological tissues. Research in this area continues to enhance the precision of drug delivery systems and tissue scaffolding, bridging material science with clinical applications.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.